Floatz logo

Roflumilast

Bronchiectasis

The University of Hong KongSmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Bronchiectasis cohort.

Asset / SponsorPhaseRating
Ciprofloxacin
Centre Hospitalier Intercommunal Creteil
Phase 4BBB
Azithromycin
Assiut University
Phase 4BBB
Lipitor
University of Edinburgh
Phase 4BB
Theophylline
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BB
Colistimethate
Centre Hospitalier Intercommunal Creteil
Phase 3BB

View all 50 →

Same molecule, other indications

Roflumilast is also rated in:

polycystic ovary syndromeDormant
BB
Indicative ·
69 / 100
View asset →
chronic obstructive pulmonary diseaseDormant
BB
Indicative ·
67 / 100
View asset →
obesity disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →